ABSTRACT Three hundred sixty-eight patients were randomly assigned to receive intravenous streptokinase (IVSK) (n = 191) or standard therapy (n = 177) to determine the efficacy of IVSK in the treatment of acute myocardial infarction. The mean time to treatment was 3.5 hr. At 14 days there were 12 deaths in the treatment group (6.3%) and 17 deaths in the control group (9.6%) (p = .23). Early mortality was related to infarct location. Fourteen day mortality for anterior infarctions was 10.4% for treatment with IVSK and 22.4% for control patients (p = .06) and was similar for IVSK-treated patients with inferior infarctions, 4.0% vs 1.8% (p = .32). For those randomized under 3 hr, 14 day mortality tends to be lower in treated patients, 5.2% vs 11.5% (p = .11). There was significant improvement in long-term survival for patients with anterior infarction; 2 year survival was 81% for IVSK-treated patients and 65% for control patients (p = .05). There was no improvement in survival for patients with inferior myocardial infarction (p = .27). We conclude that patients with anterior myocardial infarction have improved survival when treated within the first 6 hr of symptoms. Patients with inferior infarction do not appear to have improved survival with thrombolytic therapy. Some of this improvement in survival in patients with anterior infarction may be due to a higher frequency of revascularization procedures in the treatment group. Circulation 77, No. 2, 345-352, 1988. THROMBOLYTIC THERAPY for acute myocardial infarction became possible in the early part of this decade with the demonstration of the important role of coronary artery thrombosis as the immediate cause of acute myocardial infarction.1 Early reports from Russia and West Germany demonstrated the efficacy of intracoronary streptokinase in achieving coronary artery reperfusion in the setting of acute infarction.2 3 After reports of numerous pilot studies, two small randomized trials of intracoronary streptokinase were reported,4-demonstrating coronary artery reperfusion rates between 65% and 85%. Those that began streptokinase therapy within 3 hr of the onset of chest pain demonstrated evidence of myocardial salvage with an increase in ejection fraction and improved regional wall motion in the treated patients.5 These initial trials
THROMBOLYTIC THERAPY for acute myocardial infarction became possible in the early part of this decade with the demonstration of the important role of coronary artery thrombosis as the immediate cause of acute myocardial infarction.1 Early reports from Russia and West Germany demonstrated the efficacy of intracoronary streptokinase in achieving coronary artery reperfusion in the setting of acute infarction.2 3 After reports of numerous pilot studies, two small randomized trials of intracoronary streptokinase were reported,4-demonstrating coronary artery reperfusion rates between 65% and 85%. Those that began streptokinase therapy within 3 hr of the onset of chest pain demonstrated evidence of myocardial salvage with an increase in ejection fraction and improved regional wall motion in the treated patients.5 These initial trials were too small to define adequately the effect of intracoronary streptokinase on survival. Two larger studies have shown a significant reduction in early mortality.6' 7 These results of intracoronary streptokinase, as well as the knowledge that intracoronary therapy was not feasible for many patients and delayed the onset of treatment, led us to study intravenous streptokinase (IVSK) in the treatment of acute myocardial infarction. This trial was planned in the spring of 1982 and funded in August 1983, and patients were entered between September 1983 and August 1986.
Methods
The planned sample size of 660 patients was based on an assumed 14 day mortality of 14% in the controls and 7% in the treated patients. For these alternatives, 330 patients would be needed in each group to achieve a power of 0.80 with a significance level of .05. During the planned 3 years of patient entry, only 368 patients were randomized. As the results of other studies were reported,7 8 Patients randomly assigned to streptokinase therapy were given 50 mg benadryl and 100 mg hydrocortisone intravenously, followed by 1.5 thallium-201 myocardial imaging for infarct sizing and radionuclide determination of ejection fraction. These studies were done in a central laboratory 6 to 8 weeks after patients entered the study and will be reported separately.
Randomization procedure. At the beginning of the study, patients at each hospital were randomly assigned to treatment and control groups within the following strata: (1) anterior myocardial infarction less than 3 hr from onset of symptoms, (2) anterior myocardial infarction 3 to 6 hr from symptom onset, (3) inferior myocardial infarction less than 3 hr from onset of symptoms, and (4) inferior myocardial infarction 3 to 6 hr from symptom onset. Four sets of opaque, sealed envelopes were used to randomly assign patients to treatments. Each envelope contained the patient identification number and therapeutic assignment. This number, when reported to the data coordinating center, was used to ascertain that envelopes had been opened in the proper sequence and the therapeutic assignment was correct.
Clinical data collection. 10 The extent of disease in the noninfarct arteries was also classified. Reperfusion was measured as in the TIMI trial:1' grade 0, no reperfusion; grade 1, penetration of the thrombus with minimal perfusion; grade 2, partial perfusion; grade 3, complete perfusion. The angiographic reading panel was blinded to treatment assignment.
A 6 month and a second follow-up carried out at 1 or more years were accomplished by mail and/or phone. Vital status and interim coronary bypass surgery and coronary angioplasty were ascertained. Information concerning hospitalization for reinfarction, chest pain, congestive heart failure, arrhythmia, and cardiac catheterization was collected. Questions concerning the presence and frequency of angina were also asked. To date, 6 month and late follow-up have been completed for 99.7% and 98% of eligible patients.
Objectives of the study. The primary end point of the trial was 14 day mortality, and secondary end points reported here included long-term survival and the effect of treatment on coronary artery patency, left ventricular function, and the patient's initial clinical course. The results of follow-up (8 week) measurements of infarct size, segmental wall motion, and global left ventricular function will be reported later.
Statistical methods. The chi-square and Fisher's exact tests were used to test for statistical significance for categorical variables. For continuous variables, the two-tailed t test was used to determine statistical significance. Continuous variables were expressed as mean + 1 SD. The product limit method was used to test for differences in survival between treatment and control groups.
Results
Three hundred sixty-eight patients were enrolled by 80 physicians; 27 hospitals contributed an average of CIRCULATION genic shock were present in 8.4%, 4.9%, and 1.6%, respectively. Emergency direct-current defibrillation or cardioversion was required in 2.4% of patients. The average dose of streptokinase was 1,488,000 ± 122,000 IU given over a period of 60 ± 10 min.
During the first 14 days after myocardial infarction, 13 patients in the treatment group (6.8%) and 10 in the control group (5.6%) underwent coronary artery bypass graft surgery. Twelve treatment patients (6.3%) and five control patients (2.8%) had coronary balloon angioplasty during the same period (p = .11).
By 1 year, 17.3% of the treatment and 14.1% of the control patients had undergone coronary artery bypass graft surgery (CAB3G), whereas 9.9% of treatment and 4.5% of control patients had had coronary artery angioplasty. Thus 27.2% of treatment patients and 18.6% of controls had a revascularization procedure by 1 year (p = .05). There were no hospital deaths related to these procedures. One patient who had CABG died 1 week after discharge from the hospital.
Fourteen day mortality. The 14 day mortality is presented in figures 1 and 2. Overall, the mortality was 7.9%. Twelve of 191 IVSK-treated patients (6.3%o) resuscitation had contraindications to receiving streptokinase. This patient died 2 days later. Mortality was related to the location of the infarction, as shown in figure 1 . After anterior infarction, mortality was 10.5% in the treatment group and 22.4% in the control group (p = .06). Among those with inferior infarction, mortality was similar in the treatment and the control groups (4.0% vs 1.8%; p = .32). There were 34 women in the treatment group, and one died (2.9%), while four of 25 women (16.0%) in the control group died (p -.08). The mortality rates for men assigned to treatment and control were more similar, 7.0% vs 8.6% (p = .61). Among all patients with prior myocardial infarction, none of 26 treated patients and five of 23 (21.7%) control patients died (p = .02). The influence of time to randomization on 14 day survival is shown in figure 2 . For patients randomized by less than 3 hr, the treatment group had a 5.2% mortality compared with the control patients' mortality of 1 1.5% (p = . 11). There was no difference in the 14 day mortality for those randomized after 3 hr (7.5% for both groups).
Clinical status. The clinical status of patients at the time of hospital discharge is shown in table 2 and is presented according to treatment group. There were no apparent dilferences in the status of treatment and control groups. The length of stay, angina class, presence of congestive heart failure, peak CK level, and incidence of non-Q wave infarction were similar in both treatment and control groups (p > .05). The time to peak CK level was significantly earlier in treated compared with control patients (p < .0001).
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At the time of late follow-up, IVSK-treated and control patients did not differ with respect to rehospitalization for chest pain, 13.4% vs 12. 1 % (p = .74), congestive heart failure, 2.0% vs 5.3% (p = .14), arrhythmia, 4.8% vs 8.9% (p = .15), or cardiac catheterization, 9.4% vs 5.3% (p = .19). However, patients did differ with respect to rehospitalization for myocardial infarction, 9.6% of treated patients and 2.7% of controls (p = .01). Finally, the presence of angina was similar in both groups at 6 month and late followup. At late follow-up, 39.3% of IVSK-treated and 37.6% of control patients had at least some episodes of angina pectoris.
Complications of therapy. Complications occurred in 23.0% of the treatment group and in 14.1% of the control group (p = .03). Bleeding, although infrequent, tended to occur more often in the streptokinase group (13.1% vs 0.6%; p = .07), as did allergic reactions (2.1% vs 0%; p -.07). The incidence of ventricular fibrillation was similar in both groups, but ventricular tachycardia occurred more frequently in the IVSK-treated patients (11.0% vs 4.5%; p = .02). There was one serious nonfatal intracerebral hemorrhage resulting in severe permanent neurologic disability in a 66-year-old man in the IVSK group.
Angiographic findings. One hundred thirty-eight (72.3%) treated and 112 (63.3%) control patients underwent follow-up cardiac catheterization an average of 10.4 + 7.4 days after infarction. The baseline clinical characteristics of patients undergoing cardiac catheterization were evaluated. The average age of those undergoing catheterization was 55, compared with 60 for those not undergoing catheterization (p < .01). Patients with catheterization were also more Long-term survival. The survival of the treatment and control patients up to 3 years is displayed in figure 3 . The mean follow-up for all patients was 1.4 years. For the group as a whole, there was a small trend toward a reduction in mortality but the difference is not significant (p = .35). This is in contrast to the survival of the patients with anterior myocardial infarction as shown in figure 4 . Survival for IVSK-treated patients was 83% vs 70% for the controls at 1 year and 81% vs 65% at 2 years. This difference in survival was significant (p = .05) and was primarily due to the large reduction in mortality for those randomized by less than 3 hr, in whom the 1 year survival was 82% vs 60% for controls. On the other hand, there was no benefit for the patients with inferior myocardial infarction, with 1 year survival of 91% vs 95% for controls and 2 year survival of 89% vs 93% (p = .27). Patients with inferior myocardial infarction who were randomized loor between 3 and 6 hr had a trend toward reduced survival with IVSK therapy, with 1 year survival of 87% for treated patients and 96% for controls and 2 years survival of 84% vs 96% (p = .07). The initial differences in mortality for women and those with prior myocardial infarction receiving IVSK therapy were no longer evident at the time of last follow-up.
Discussion
This randomized trial was stopped after the entry of 368 patients over the prescribed period of 36 months. The decision to halt the trial was made after the publication of the early results of two large IVSK trials, the ISAM trial from the Federal Republic of Germany12 13 and the much larger GISSI from Italy.8 14 in this report. These results represent a reduction in early mortality of 34% in this study, 1 1% in the ISAM study, 18% in GISSI, and approximately 33% in ISIS-2. A positive trend in mortality was therefore present in each trial but varied in magnitude and achieved statistical significance in the two largest trials.
The major benefit of IVSK in this trial was in patients with anterior infarction and in those randomized by less than 3 hr from onset of symptoms. This corresponds to those treated patients who had higher ejection fractions at 1 to 3 week angiography. These were also the groups of patients who benefited most in GISSI. Equally important, as in GISSI, this trial demonstrated no benefit from IVSK in patients with inferior myocardial infarctions. As demonstrated by GISSI, the time to onset of IVSK therapy is of major importance. The prolonged interval between hospitalization and onset of therapy of more than 1.5 hr in this trial no doubt reduced the potential efficacy of IVSK therapy and highlights the need for the expeditious management of these patients.
The trend toward reduced 14 day mortality in the subsets of patients with prior myocardial infarction and women in this trial is of interest. It is important, however, to recognize the small numbers ofpatients in these subgroups. The German study did not report mortality for these subsets. In GISSI, the mortality for women was reduced with therapy from 22.6% in the controls to 18.5% (p = .01) in treated patients. In this study there was a strong trend in the same direction, with the control women having a mortality of 16.0% and the treated patients 2.8% (p = .08). This is in contrast to the mortality for patients with a history of prior myocardial infarction. In this group there was a statistically significant reduction in mortality in the treated patients CIRCULATION in this study, 0% in the treated patients and 21.7% (p = .02) in the controls. There was no such trend in the GISSI study, with the mortality being 16.9% in the treated and 16.5% in the control patients (p = NS).
We have no explanation for these differences. We anticipated that the patients at highest risk would be the group that would benefit most from thrombolytic therapy. This has been the case in the subsets of patients in this trial and in our prior intracoronary streptokinase trial,6 but it is difficult to discard the results obtained by GISSI. Possibly a more detailed analysis of the GISSI study will help to provide an explanation. It should be remembered that GISSI accepted patients up to 12 hr after the onset of symptoms as well as those over 75 years of age. The subset analysis available at this time does not take into account the time of treatment or the age of the patients. For the purpose of this discussion, we are therefore comparing the results in our patients under age 76 and treated at less than 6 hr from the onset of symptoms with an older group of patients treated up to 12 hr. Thus the difference in the patient populations may account for some of the differences in results.
Both this study and the German study show improvements in the ejection fraction for patients receiving early therapy. For those randomized by less than 3 hr from the onset of symptoms, in this trial the ejection fraction was 56% for treated patients and 52% for control patients (p = .20). For those treated by less than 3 hr in the German study the ejection fraction was 57% vs 54%, respectively (p < .005). The difference was most striking for patients with anterior infarction in this trial (53% vs 44%; p = .03). The 2, February 1988 revascularization (27.2%) in the treatment group during the first year after myocardial infarction was more than twice that in the ISAM trial (12.5%) and may in part explain the sustained long-term survival of patients in this study as compared with the ISAM experience. 13 The trend toward reduced heart failure in treated patients at late follow-up is consistent with the observed improvement in ejection fraction. This benefit is partially offset by the higher reinfarction rate for IVSK-treated patients. More frequent reinfarction among treated patients has also been reported by ISAM and GISSI investigators. It is not known whether more aggressive use of revascularization procedures after thrombolysis can further minimize the occurrence of reinfarction.
In summary, the Western Washington IVSK trial has demonstrated improved survival in patients with anterior myocardial infarction. IVSK did not improve survival of patients with inferior myocardial infarction. Patients in the treatment group also had higher rates of coronary artery patency at 1 and 3 week angiography as compared with controls, and this was most evident in the patients randomized in less than 3 hr in whom the left anterior descending coronary artery was the infarct vessel. Left ventricular function was significantly improved in patients with anterior myocardial infarctions and in those with patent infarct vessels at the time of follow-up angiography with a trend toward improved function in the treatment group as a whole.
Based on the results of this randomized trial, we conclude that IVSK, when given within the first few hours of evolving anterior myocardial infarction, improves early and late survival. This improved survival may depend on the relatively frequent use of additional revascularization procedures after therapy.
The efficacy of IVSK in the treatment of patients with inferior myocardial infarction has not been demonstrated by this or other trials and cannot be recommended at this time.
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